Dbi
Dbi Uses, Dosage, Side Effects, Food Interaction and all others data.
A biguanide hypoglycemic agent with actions and uses similar to those of metformin. Although it is generally considered to be associated with an unacceptably high incidence of lactic acidosis, often fatal, it is still available in some countries. (From Martindale, The Extra Pharmacopoeia, 30th ed, p290)
Used to treat diabetes, phenformin is a biguanide (contains 2 guanidino groups) hypoglycemic agent with actions and uses similar to those of metformin (Glucophage). Both drugs work by (1) decreasing the absorption of glucose by the intestines, (2) decreasing the production of glucose in the liver, and by (3) increasing the body's ability to use insulin more effectively. More specifically, phenformin improves glycemic control by improving insulin sensitivity. Dbi is generally considered to be associated with an unacceptably high incidence of actic acidosis. In general biguanides should be used only in stable type II diabetics who are free of liver, kidney and cardiovascular problems and who cannot be controlled with diet.
| Trade Name | Dbi |
| Generic | Phenformin |
| Phenformin Other Names | Fenformin, Fenformina, Phenformin, Phenformine, Phenforminum |
| Weight | 25mg, |
| Type | Tablet |
| Formula | C10H15N5 |
| Weight | Average: 205.2596 Monoisotopic: 205.132745505 |
| Groups | Approved, Investigational, Withdrawn |
| Therapeutic Class | |
| Manufacturer | Usv Pvt Ltd |
| Available Country | India, |
| Last Updated: | September 19, 2023 at 7:00 am |
Uses
For the reatment of type II diabetes mellitus.
How Dbi works
Dbi binds to the AMP-activated protein kinase (AMPK). AMPK is an ultra-sensitive cellular energy sensor that monitors energy consumption and down-regulates ATP-consuming processes when activated. The biguanide phenformin has been shown to independently decrease ion transport processes, influence cellular metabolism and activate AMPK. Dbi's hypoglycemic activity is related the effect it has in activating AMPK and fooling insulin sensitive cells into thinking that insulin levels are low and causing the body to use glucose as if in a state of low caloric consumption. This drug also seems to inhibit several varients of ATP-sensitive potassium channels (namely the receptor subtype Kir6.1).
Innovators Monograph
You find simplified version here Dbi
